nach oben

Endocrine

Erschienen in:

01.06.2014 | Original Article

Functional thyrotropin receptor expression in the ventricle and the effects on ventricular BNP secretion

verfasst von: Wen Huang, Jin Xu, Fei Jing, Wen-Bin Chen, Ling Gao, Hai-Tao Yuan, Jia-Jun Zhao

Erschienen in: Endocrine | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Elevated thyrotropin (TSH) and hypercholesterolemia commonly coexist in patients with subclinical hypothyroidism, which can cause and aggravate heart disease. However, it is unclear whether TSH has a direct effect on cardiac function. To determine the expression of the thyrotropin receptor (TSHR) and the effects of TSH on ventricular function, we analyzed the ventricular tissues and thyroid glands from normal rats and mice and the H9c2 cardiomyocyte cell line. The results revealed that TSHR was expressed at the transcriptional and protein levels by PCR, immunoblotting, immunohistochemistry and immunofluorescence. The mRNA levels of β-MHC and the expression of pCREB and HMGCR in the ventricle were significantly lower in Tshr ^−/− mice than in wild-type (WT) mice (p < 0.05), but serum NT-proBNP levels were similar between WT and Tshr ^−/− mice. After synchronization, H9c2 cells were stimulated with several concentrations of TSH for various time periods. TSH up-regulated β-MHC mRNA expression in H9c2 cells. Cyclic adenosine monophosphate (cAMP) production and downstream signaling, such as pCREB and HMGCR expression and NT-proBNP secretion, increased in dose- and time-dependent manners. The TSH-stimulated effects were suppressed by an adenylyl cyclase inhibitor, a protein kinase A (PKA) inhibitor and HMGCR inhibitors (all p < 0.05). The data indicate functional TSHR is expressed in ventricular myocytes and mediates TSH-induced BNP secretion and HMGCR up-regulation through the cAMP/PKA/pCREB signaling pathway. Our findings suggest a potentially novel pathophysiological role of TSH in heart failure-associated hypothyroidism.

W.I. Khalife, Y.D. Tang, J.A. Kuzman, T.A. Thomas, B.E. Anderson, S. Said, P. Tille, E.H. Schlenker, A.M. Gerdes, Treatment of subclinical hypothyroidism reverses ischemia and prevents myocyte loss and progressive LV dysfunction in hamsters with dilated cardiomyopathy. Am. J. Physiol. 289(6), H2409–H2415 (2005). doi:10.1152/ajpheart.00483.2005

N. Rodondi, D.C. Bauer, A.R. Cappola, J. Cornuz, J. Robbins, L.P. Fried, P.W. Ladenson, E. Vittinghoff, J.S. Gottdiener, A.B. Newman, Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health study. J. Am. Coll. Cardiol. 52(14), 1152–1159 (2008). doi:10.1016/j.jacc.2008.07.009 PubMedCentralPubMedCrossRef

N. Rodondi, A.B. Newman, E. Vittinghoff, N. de Rekeneire, S. Satterfield, T.B. Harris, D.C. Bauer, Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch. Intern. Med. 165(21), 2460–2466 (2005). doi:10.1001/archinte.165.21.2460 PubMedCrossRef

M.D. Danese, P.W. Ladenson, C.L. Meinert, N.R. Powe, Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J. Clin. Endocrinol. Metab. 85(9), 2993–3001 (2000)PubMed

A.E. Hak, H.A. Pols, T.J. Visser, H.A. Drexhage, A. Hofman, J.C. Witteman, Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann. Intern. Med. 132(4), 270–278 (2000)PubMedCrossRef

J.P. Walsh, A.P. Bremner, M.K. Bulsara, P. O’Leary, P.J. Leedman, P. Feddema, V. Michelangeli, Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch. Intern. Med. 165(21), 2467–2472 (2005). doi:10.1001/archinte.165.21.2467. 165/21/2467 [pii]PubMedCrossRef

C. Xu, X. Yang, W. Liu, H. Yuan, C. Yu, L. Gao, J. Zhao, Thyroid stimulating hormone, independent of thyroid hormone, can elevate the serum total cholesterol level in patients with coronary heart disease: a cross-sectional design. Nutr. Metab. 9(1), 44 (2012). doi:10.1186/1743-7075-9-44 CrossRef

F. Wang, Y. Tan, C. Wang, X. Zhang, Y. Zhao, X. Song, B. Zhang, Q. Guan, J. Xu, J. Zhang, D. Zhang, H. Lin, C. Yu, J. Zhao, Thyroid-stimulating hormone levels within the reference range are associated with serum lipid profiles independent of thyroid hormones. J. Clin. Endocrinol. Metab. 97(8), 2724–2731 (2012). doi:10.1210/jc.2012-1133 PubMedCrossRef

E. Martinez-Quintana, F. Rodriguez-Gonzalez, V. Nieto-Lago, Subclinical hypothyroidism in grown-up congenital heart disease patients. Pediatr. Cardiol. 34(4), 912–917 (2013). doi:10.1007/s00246-012-0571-6 PubMedCrossRef

10.

J.L. Goldstein, M.S. Brown, Regulation of the mevalonate pathway. Nature 343(6257), 425–430 (1990). doi:10.1038/343425a0 PubMedCrossRef

11.

M. Takemoto, J.K. Liao, Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21(11), 1712–1719 (2001)PubMedCrossRef

12.

K. Kato, A.D. Cox, M.M. Hisaka, S.M. Graham, J.E. Buss, C.J. Der, Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA 89(14), 6403–6407 (1992)PubMedCentralPubMedCrossRef

13.

S.J. Fuller, J. Gillespie-Brown, P.H. Sugden, Oncogenic src, raf, and ras stimulate a hypertrophic pattern of gene expression and increase cell size in neonatal rat ventricular myocytes. J. Biol. Chem. 273(29), 18146–18152 (1998)PubMedCrossRef

14.

P. Mathiyalagan, L. Chang, X.J. Du, A. El-Osta, Cardiac ventricular chambers are epigenetically distinguishable. Cell Cycle 9(3), 612–617 (2010)PubMedCrossRef

15.

L. D’Amico, I.C. Scott, B. Jungblut, D.Y. Stainier, A mutation in zebrafish hmgcr1b reveals a role for isoprenoids in vertebrate heart-tube formation. Curr. Biol. 17(3), 252–259 (2007). doi:10.1016/j.cub.2006.12.023 PubMedCrossRef

16.

G. Deshpande, A. Godishala, P. Schedl, Ggamma1, a downstream target for the hmgcr-isoprenoid biosynthetic pathway, is required for releasing the Hedgehog ligand and directing germ cell migration. PLoS Genet. 5(1), e1000333 (2009). doi:10.1371/journal.pgen.1000333 PubMedCentralPubMedCrossRef

17.

T. Aoyagi, F. Nakamura, T. Tomaru, T. Toyo-Oka, Beneficial effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac function in ischemic and nonischemic heart failure. Intern. Heart J. 49(1), 49–58 (2008)CrossRef

18.

K. Node, M. Fujita, M. Kitakaze, M. Hori, J.K. Liao, Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108(7), 839–843 (2003). doi:10.1161/01.CIR.0000084539.58092.DE PubMedCentralPubMedCrossRef

19.

D. Grieco, Z.H. Beg, A. Romano, M. Bifulco, S.M. Aloj, Cell cycle progression and 3-hydroxy-3-methylglutaryl coenzyme A reductase are regulated by thyrotropin in FRTL-5 rat thyroid cells. J. Biol. Chem. 265(31), 19343–19350 (1990)PubMed

20.

L. Tian, Y. Song, M. Xing, W. Zhang, G. Ning, X. Li, C. Yu, C. Qin, J. Liu, X. Tian, X. Sun, R. Fu, L. Zhang, X. Zhang, Y. Lu, J. Zou, L. Wang, Q. Guan, L. Gao, J. Zhao, A novel role for thyroid-stimulating hormone: up-regulation of hepatic 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate-responsive element binding protein pathway. Hepatology 52(4), 1401–1409 (2010). doi:10.1002/hep.23800 PubMedCrossRef

21.

R. Baliram, L. Sun, J. Cao, J. Li, R. Latif, A.K. Huber, T. Yuen, H.C. Blair, M. Zaidi, T.F. Davies, Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signaling. J. Clin. Investig. 122(10), 3737–3741 (2012). doi:10.1172/JCI63948 PubMedCentralPubMedCrossRef

22.

M. Ren, Q. Guan, X. Zhong, B. Gong, Y. Sun, W. Xin, J. Guo, H. Wang, L. Gao, J. Zhao, Phosphatidylinositol 3-kinase/nuclear factor-kappa B signaling pathway is involved in the regulation of IGF-I on Fas-associated death domain-like interleukin-1-converting enzyme-inhibitory protein expression in cultured FRTL thyroid cells. J. Mol. Endocrinol. 38(6), 619–625 (2007). doi:10.1677/JME-07-0020 PubMedCrossRef

23.

W. Zhang, L.M. Tian, Y. Han, H.Y. Ma, L.C. Wang, J. Guo, L. Gao, J.J. Zhao, Presence of thyrotropin receptor in hepatocytes: not a case of illegitimate transcription. J. Cell Mol. Med. 13(11–12), 4636–4642 (2009). doi:10.1111/j.1582-4934.2008.00670.x PubMedCrossRef

24.

R. Paschke, V. Geenen, Messenger RNA expression for a TSH receptor variant in the thymus of a two-year-old child. J. Mol. Med. 73(11), 577–580 (1995)PubMedCrossRef

25.

T. Endo, K. Ohta, K. Haraguchi, T. Onaya, Cloning and functional expression of a thyrotropin receptor cDNA from rat fat cells. J. Biol. Chem. 270(18), 10833–10837 (1995)PubMedCrossRef

26.

M. Mengistu, Y.G. Lukes, E.V. Nagy, H.B. Burch, F.E. Carr, S. Lahiri, K.D. Burman, TSH receptor gene expression in retroocular fibroblasts. J. Endocrinol. Invest. 17(6), 437–441 (1994)PubMed

27.

V. Drvota, A. Janson, C. Norman, C. Sylven, J. Haggblad, M. Bronnegard, C. Marcus, Evidence for the presence of functional thyrotropin receptor in cardiac muscle. Biochem. Biophys. Res. Commun. 211(2), 426–431 (1995). doi:10.1006/bbrc.1995.1831 PubMedCrossRef

28.

D.F. Sellitti, R. Hill, S.Q. Doi, T. Akamizu, J. Czaja, S. Tao, H. Koshiyama, Differential expression of thyrotropin receptor mRNA in the porcine heart. Thyroid 7(4), 641–646 (1997)PubMedCrossRef

29.

B.E. Busuttil, A.G. Frauman, Extrathyroidal manifestations of Graves’ disease: the thyrotropin receptor is expressed in extraocular, but not cardiac, muscle tissues. J. Clin. Endocrinol. Metab. 86(5), 2315–2319 (2001)PubMed

30.

B. Biondi, Mechanisms in endocrinology: heart failure and thyroid dysfunction. Eur. J. Endocrinol./Eur. Fed. Endocr. Soc. 167(5), 609–618 (2012). doi:10.1530/EJE-12-0627 CrossRef

31.

G. Iervasi, G. Nicolini, Thyroid hormone and cardiovascular system: from basic concepts to clinical application. Intern. Emerg. Med. 8(Suppl 1), S71–S74 (2013). doi:10.1007/s11739-013-0911-4 PubMedCrossRef

32.

T.L. Broderick, M. Jankowski, D. Wang, B.A. Danalache, C.R. Parrott, J. Gutkowska, Downregulation in GATA4 and Downstream Structural and Contractile Genes in the db/db Mouse Heart. ISRN Endocrinol. 2012, 736860 (2012). doi:10.5402/2012/736860 PubMedCentralPubMedCrossRef

33.

W.J. Remme, K. Swedberg, Task force for the, D., treatment of chronic heart failure, E.S.o.C.: guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. 22(17), 1527–1560 (2001). doi:10.1053/euhj.2001.2783 PubMedCrossRef

34.

P.F. Downie, S. Talwar, I.B. Squire, J.E. Davies, D.B. Barnett, L.L. Ng, Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: implications for assessment of left ventricular dysfunction. Clin. Sci. 97(3), 255–258 (1999)PubMedCrossRef

35.

S.J. Watkins, G.M. Borthwick, H.M. Arthur, The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro. In vitro cellular & developmental biology. Animal 47(2), 125–131 (2011). doi:10.1007/s11626-010-9368-1

36.

T. Kimura, A. Van Keymeulen, J. Golstein, A. Fusco, J.E. Dumont, P.P. Roger, Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr. Rev. 22(5), 631–656 (2001)PubMedCrossRef

37.

A. Bell, A. Gagnon, P. Dods, D. Papineau, M. Tiberi, A. Sorisky, TSH signaling and cell survival in 3T3-L1 preadipocytes. Am. J. Physiol. Cell Physiol. 283(4), C1056–C1064 (2002). doi:10.1152/ajpcell.00058.2002 PubMedCrossRef

Titel: Functional thyrotropin receptor expression in the ventricle and the effects on ventricular BNP secretion
verfasst von: Wen Huang
Jin Xu
Fei Jing
Wen-Bin Chen
Ling Gao
Hai-Tao Yuan
Jia-Jun Zhao
Publikationsdatum: 01.06.2014
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 2/2014
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-013-0052-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Functional thyrotropin receptor expression in the ventricle and the effects on ventricular BNP secretion

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Healthy lifestyle for metabolic health: no more excuse!

Cabergoline treatment in acromegaly: cons

Lupus nephritis with positive myeloperoxidase/proteinase 3-antineutrophil cytoplasmic autoantibody that developed after 17 years of propylthiouracil therapy

Hyperhomocysteinemia is an independent predictor of sub-clinical carotid vascular damage in subjects with grade-1 hypertension

Clinical implication of elevated CA 19-9 level and the relationship with glucose control state in patients with type 2 diabetes

Selective blockade of estrogen receptor beta improves wound healing in diabetes

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin